Navigation Links
Nuevolution Announces New Research Collaboration With Big Pharma
Date:8/31/2009

COPENHAGEN, August 31 /PRNewswire/ --

- Partnership to use Nuevolution's Chemetics(R) Technology for Lead Discovery

Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis.

During the collaboration, Nuevolution will apply its proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against drug targets of interest to Novartis. The Chemetics(R) platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale.

Nuevolution will screen its multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics(R) follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

Under the terms of the agreement, Novartis will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.

"We are delighted that Novartis has elected to enter this collaboration with Nuevolution" said Alex Gouliaev, CEO of Nuevolution A/S, and continued: "We look forward to an exciting and fruitful outcome of the collaboration."

About Nuevolution

Nuevolution is a leading lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing lead discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Invest and Novo A/S. For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com

    For further information about Nuevolution please contact:
    Nuevolution A/S
    Alex Haahr Gouliaev, CEO
    +45-3913-0987
    ahg@nuevolution.com



'/>"/>
SOURCE Nuevolution
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. REES Announces New San Antonio Office
2. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
3. ReBuilder Medical Technologies, Inc. Announces Negotiations with National Medicare Provider
4. ALOKA Announces New ProSound Alpha Series Ultrasound System
5. Snoring Isn't Sexy, LLC Announces the Launch of E-cards for Snorers
6. The Cosmetic Bootcamp LLC Announces Novel Presentations at Its 3rd Annual Marketing and Management Symposium
7. ReBuilder Medical Technologies, Inc. Announces Second Quarter 2009 Profits up 100%
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
9. M-TEC Announces Leadership Changes and a Commitment to Serving as Innovators in the Medical Transcription Industrys Evolution
10. Linkwell Corporation Announces Launch of the Establishment of 100 Model Hospitals Across China
11. CMSA Announces New Model ACT Supporting Case Management Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: